Refine by
Infection Detection From Blood Articles & Analysis: Older
22 news found
Acinetobacter is described by the Centers for Disease Control and Prevention (CDC) as a group of bacteria commonly found in the environment. While there are many types, the most frequent cause of infections in humans is Acinetobacter baumannii. Infections of the blood, urinary tract, and lungs, or in wounds in other parts of the body can all be caused by Acinetobacter baumannii. It can also ...
The Centers for Disease Control and Prevention describe Acinetobacter as a group of bacteria commonly found in the environment in places like soil and water. While there are many types, the most frequent cause of infections in humans is known as Acinetobacter baumannii. Those most at risk of infection according to the CDC include patients in hospitals, especially those who: · are ...
Acinetobacter is described by the Centers for Disease Control and Prevention (CDC) as a group of bacteria commonly found in the environment in places like soil and water. While there are many types, the most frequent cause of infections in humans is known as Acinetobacter baumannii. Infections of the blood, urinary tract and lungs, or in wounds in other parts of the body can all be caused by ...
OKLAHOMA CITY, Oklahoma – Linear Health Sciences, developer of the Orchid™ Safety Release Valve (SRV), announced that it has received a substantial grant to work with the Global Center for Medical Innovation. GCMI is a comprehensive medical-device innovation center that guides the development and commercialization of new medical devices. Linear Health Sciences is the first company to ...
ATLANTA, Georgia – The early success of Linear Health Sciences in developing its Orchid™ Safety Release Valve to prevent unwanted dislodgement of IV catheters was highlighted in a panel discussion at the recent annual conference of the Southeastern Medical Device Association (SEMDA). Dan Clark, co-founder and Chief Marketing Officer of Linear Health Sciences, represented the company ...
Portsmouth, N.H. – IV dislodgement is a near-daily problem for clinicians and their patients, according to a recent focus group of vascular access experts. The clinicians also reported there is a need for better technology to mitigate the potentially serious consequences of frequent IV dislodgements. “This research discussion addressed a frustrating problem that those of us in ...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that treat urothelial and specialty cancers, today announced the first published report of real-world experience utilizing the antegrade approach for Jelmyto® (mitomycin) for pyelocalyceal solution administration in the Journal of Urology online on February 7, 2022. This report provides a stepwise ...
MHA Solutions and Magnolia Medical will also be sponsoring roundtable symposiums with C-suite executives from MHA member hospitals on the national movement to a new 1% or below blood culture contamination rate, a significant reduction from the current national target benchmark of 3%. Blood culture is the gold standard for ...
Specific Diagnostics today announced formation of its US commercial sales, service, support and marketing teams in anticipation of the launch of the Reveal Rapid AST System for blood infection samples. Following 11 studies across France and England comprising over 1,400 clinical positive blood culture samples, yielding overall accuracy of 97.8%, ...
Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing1, commended U.S. Representatives Mike Levin (D-CA), Gus Bilirakis (R-FL), and eight of their colleagues for sending a joint, bipartisan letter urging the Centers for Medicare and Medicaid Services (CMS), an agency within ...
“Having participated in the development of the rapid ID market with GenMark’s syndromic PCR solution, I know from that our leading customers now need an affordable, high throughput, and easy to use rapid AST, especially for blood infections. ...
The six studies reported reductions in blood culture contamination ranging from 80% to 100% with sustained rates of less than 1% in each. ...
Specific Diagnostics announces today the commencement of its US clinical studies for the Reveal Rapid AST System for blood infection. Trials will entail 3 months of data collection followed by submission for FDA consideration of 510(k) clearance of the Reveal test. ...
Why HIV Testing is Important HIV Testing is critical to reducing its spread. The CDC recommends that all people ages 13-64 get tested at least once, and individuals deemed high risk should be tested more frequently. A positive test allows individuals to then seek treatment (there are several forms of effective treatment currently available) and prevent transmission to others. How HIV Testing ...
ByFluxergy
While rapid ID instrumentation for blood stream infections is now widely available, clinicians often wait additional 1 to 2 days to receive the AST results required to identify the optimal antibiotic therapy, which the ID result alone does not enable. ...
In Patients Who Receive Ineffective Empirical Antibiotics for Blood Stream Infections (BSI), Use of AXDX Was Associated With Reduction in 30-Day Mortality Interim Data From Multicenter Study Highlight the Real-World Clinical Utility of Fast Phenotypic Antimicrobial Susceptibility Testing for BSI Across Diverse Healthcare Settings and Patient Populations Accelerate Diagnostics, Inc. ...
Cytovale, Inc., a medical technology company dedicated to revolutionizing diagnostics using cell mechanics and machine learning, has received an AACC Academy’s Distinguished Abstract Award for its abstract titled “Rapidly Assessing the Host Immune Response for the Diagnosis of Sepsis, a Prospective Multi-Site Clinical Study in the Emergency Department (ED) Employing the Leukocyte ...
Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, announced findings from a new study published today in Nature Communications that demonstrate its ability to identify patients with bacterial versus viral infections using a data-driven approach that measures the immune system response. The molecular classifier used in the study forms the ...
San Francisco medical device company Velano Vascular closed a $25 million second round of financing, bringing its total overall to $50 million. The new capital will go toward expanding its needle-less blood draw device and to developing new technologies. CEO Eric Stone would not reveal what these new technologies will entail but said they will fall within the company’s mission ...
AVA Scientific Meeting 2019 highlights key opportunities for improvement in vascular access from process bundles to emerging new products Introduction Acknowledgment of the importance of the vascular access nurse and team were obvious at this year’s Association for Vascular Access (AVA) Annual Scientific meeting. When Ramzy Nasrallah took over as CEO for the Association of Vascular Access ...